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Abstract 
Cancer stem cells (CSCs) appear to resist chemo-radiotherapy and initiate tumor recurrence in 
patients. Isolation and further characterization of this subpopulation is important for targeting 
CSCs. Flow cytometry using Aldefluor, a fluorescent substrate of aldehyde dehydrogenase, has 
been used to isolate CSCs from various cancer cell lines. However, new techniques are needed to 
locate and identify CSCs in culture for live-cell analyses such as fluorescence microscopy without 
introducing artifacts during cell sorting and to observe CSC and non-CSC interactions. Previously, 
we characterized a distinct CSC subpopulation within human esophageal cancer cell lines (ESCC). 
In this study we introduce the attached-cell Aldefluor method (ACAM) to detect CSCs in ESCC 
cell lines (KY-5, KY-10, TE-1, TE-8, YES-1, YES-2). To validate this technique, we isolated CSCs 
from the YES-2 parental line using standard Aldefluor flow cytometry to create a cell line enriched 
in CSCs (YES-2CSC). This line showed significantly greater ACAM staining and higher CD44 levels 
than YES-2. ACAM also showed significantly higher ALDH activity in YES-2CSC than in YES-2S, a 
cell line that has a diminished CSC subpopulation after having survived treatment with curcumin. 
ACAM stained cells within tumorspheres made from the CSC-enriched line but not differentiating 
cells from the tumorspheres. This study also demonstrates a new method for generating and 
growing tumorspheres without the growth factor supplements normally used in medium to form 
tumorspheres. ACAM should be evaluated using other cancer cell lines to further substantiate its 
effectiveness and to characterize CSCs in culture through various imaging techniques. 
Key words: Esophageal Cancer, Cancer Stem Cells, Aldefluor, Adherent Cells, CD44, Tu-
morsphere, Curcumin. 
Introduction 
Recent studies show that many solid tumors 
contain a subpopulation of cells known as cancer stem 
cells (CSCs) 1, 2. CSCs display stem cell characteristics 
including self-renewal and differentiation into a het-
erogeneous population of cancer cells consisting of 
progenitor cells and more differentiated cancer cells 
3-5. It is likely that CSCs are responsible for initiation, 
progression, recurrence, metastasis, and chemo- 
radiotherapy resistance 6, 7. Additional methods to 
identify and isolate CSCs are needed for their func-
tional characterization and to develop effective ther-
apeutics targeting this cell subpopulation 8. CSCs 
have been identified and isolated from different can-
cer cell lines using several techniques. Tumor for-
mation by CSCs in vivo is the most definitive method 
for identifying these cells, but several in vitro methods 
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are also effective. For example, fluorescence-activated 
cell sorting (FACS) or magnetic cell separation are 
used to isolate CSCs based on expression of specific 
cell markers, such as the expression of CD24, CD44, 
and CD133 9-11, although the presence of these surface 
proteins varies considerably among CSCs of different 
cancers. Another method is to use the fluorescent 
Hoechst 33342 dye, which is used to isolate a 
Hoechst-negative CSC “side population” 12. With this 
method, however, the possible toxicity of the dye may 
cause side effects during cell sorting 13, 14.  
CSCs often have significantly elevated aldehyde 
dehydrogenase (ALDH) activity 15. A substrate for 
ALDH1, Aldefluor, was initially developed to isolate 
hematopoietic stem cells using FACS 16. This Alde-
fluor method has been applied for separation of CSCs 
from tumor tissue and cancer cell lines 17, 18. Aldefluor 
has been used successfully to detect elevated ALDH1 
activity in stem and progenitor cells of lung 18, pros-
tate 19, breast 20, colon 21 and bladder 22 cancers. 
Aldefluor contains the ALDH1 substrate 
BODIPY-aminoacetaldehyde (BAAA) that is con-
verted by ALDH1 into the fluorescent product 
BODIPY-aminoacetate (BAA) 16, as described in the 
product literature (Stem Cell Technologies). Live cells 
retain BAA because of its charge and also because the 
multidrug-resistance transporters are intentionally 
inhibited by the Aldefluor reagents. Aldefluor treated 
cells expressing high levels of ALDH1 activity have 
high fluorescence and can be isolated with FACS into 
two subpopulations—ALDH-hi and ALDH-low 17. Even 
though this method has been used to identify CSCs 
and has been validated for some cancers, it has not 
been employed as widely as techniques that identify 
CSC surface markers such as CD44 or CD133 23. 
Although these flow cytometry methods are ef-
fective for quantifying CSCs and enriching the CSC 
content of cell cultures, they have drawbacks and 
limitations concerning the handling of the cells 24. For 
example, they require cell trypsinization to produce 
cells in suspension and in this state cells clump to-
gether and metabolism may be altered by poor access 
to the medium. Cell handling can also induce stress, 
disrupt gene expression, and lead to altered cell 
physiology. To extend the usefulness of Aldefluor as a 
stem cell marker, we assessed the use of Aldefluor 
staining in cancer cells in adherent cell cultures, which 
resulted in the attached-cell Aldefluor method 
(ACAM). Being able to identify stem cells in live cell 
monolayers with a technique such as ACAM has sev-
eral advantages: (1) single-cell imaging of physiolog-
ical processes within CSCs is much more practical in 
monolayers than with cells in suspension or tu-
morsphere cultures, the typical method for growing 
CSCs 25; (2) the viability of CSCs in tumorspheres is 
highly variable depending on cell access to the me-
dium and effects from the microenviroment, whereas 
monolayers have more uniform access to nutrients, 
oxygen and mitogens such as epidermal growth factor 
(EGF) and basic fibroblast growth factor (bFGF) 26, 27; 
and (3) derivation of CSC cultures from tumors would 
be aided by being able to identify live CSCs in mono-
layers 26. However, the standard Aldefluor technique 
in which cells in suspension are stained remains a 
valuable method for separating and collecting CSCs 
from cultures. 
Here we describe the use of ACAM with six 
esophageal squamous cell carcinoma (ESCC) cell lines 
that were used previously to evaluate curcumin ef-
fects on CSCs 28, Curcumin, an ingredient of the spice 
turmeric, inhibits cancer cell growth 29, 30 including 
ESCCs 31, 32 and reduces the number of CSCs in cancer 
cell lines relative to the more differentiated cancer 
cells 28, 33-35. One of our CSC-depleted ESCC lines, 
YES-2S, that had survived curcumin treatment 28 was 
used in the current study. In addition, to create a cell 
line enriched in CSCs standard Aldefluor flow cy-
tometry was applied to one of the ESCC lines, YES2, 
and tested with ACAM. 
CSCs have also been identified by their ability to 
form tumorspheres in medium containing specific 
growth factors 36, 37. Tumorspheres are enriched in 
CSCs and the stem-like progenitor cells differentiating 
from CSCs 38. We applied Aldefluor directly to ESCC 
tumorspheres to test whether the cell types within the 
tumorspheres could be distinguished by fluorescence 
microscopy. Aldefluor has been used to detect CSCs 
in cell suspensions derived from tumorspheres 39, 40, 
but has not been used to stain intact tumorspheres in 
culture. To further characterize tumorspheres in terms 
of their CSC content, we examined tumorsphere for-
mation, growth, sensitivity to curcumin, and ALDH1 
activity. The present study discusses the potential 
benefits of ACAM for investigating individual CSCs 
in culture and is the first to demonstrate the useful-
ness of Aldefluor imaging in cancer cells growing as 
monolayers or tumorspheres. 
Materials and Methods 
Cell lines and culture conditions 
Human ESCC lines (KY-5, KY-10, TE-1, TE-8, 
YES-1, and YES-2) were provided from various 
sources 41-44, and they were previously characterized 
immunologically and morphologically in our labora-
tory 28, 45 Cells were grown in a medium designated as 
Complete medium that consisted of Dulbecco's modi-
fied Eagle medium (DMEM) containing penicillin (100 
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units/ml), streptomycin (100 µg/ml), L-glutamine (2 
mM) (Life Technologies, Grand Island, NY), and 10% 
fetal bovine serum (FBS, Summit Biotechnology, Ft. 
Collins, CO). Cells were grown in 100-mm tissue cul-
ture dishes (Falcon, Lincoln Park, NJ) at 37°C in 100% 
humidity and 5% CO2. Cells were passaged when 
they reached near confluency as described 
previously28. 
Aldefluor assay and separation of cells with 
high-ALDH activity 
ALDH activity was assayed in the YES-2 cell line 
using the Aldefluor kit according to the manufactur-
er’s instructions (STEMCELL Technologies, Vancou-
ver, BC, Canada). Briefly, 3 ml of a cell suspension (106 
cells/ml in DMEM without serum) was centrifuged at 
250 x g and resuspended in 3 ml of Aldefluor Buffer 
on ice. To produce the fluorescent product, 45 μl of 
activated Aldefluor substrate was mixed with 3 ml of 
the cell suspension. Immediately after mixing, 1 ml 
was used as the negative control by adding 30 μl of 
diethylaminobenzaldehyde (DEAB), the ALDH1 in-
hibitor. The test sample and negative control were 
incubated for 45 min at 37°C and agitated every 5 min. 
These cells were centrifuged and resuspended in Al-
defluor Buffer and kept on ice for one hour. The cells 
were separated by flow cytometry using a FACSAria 
III (BD Biosciences, San Jose, CA) based on fluores-
cence and cell scattering into two subpopula-
tions—CSCs and non-CSCs. FACS was performed at 
the Flow Cytometry Core Facility, University of To-
ledo, OH. After separation, cells were plated, grown 
in culture, and stored at -80°C for future experiments. 
Cell sorting data were analyzed with WinMDI 2.8 
software. 
Attached-cell Aldefluor method (ACAM)  
To evaluate ACAM’s ability to determine 
ALDH1 activity in ESCC lines, Aldefluor reagent was 
used to stain attached ESCC cells. Each cell line was 
grown on 25-mm glass coverslips in Complete me-
dium. After 48 hours, the coverslips were washed 
with Hank's Buffered Salt Solution (HBSS). One ml of 
Aldefluor Buffer was added to 15 μl of activated Al-
defluor, and 200 μl of this solution was added to each 
coverslip which were then incubated for 45 min at 
37°C in an incubator supplied with humidified air 
containing 5% CO2. Next, the coverslips were washed 
three times with HBSS and inverted on a chamber 
containing 100 μl HBSS mounted on a glass micro-
scope slide. Control coverslips did not receive the 
activated Aldefluor, but were otherwise treated iden-
tically. The cells were examined with a fluorescence 
microscope (Zeiss Axiophot, Carl Zeiss Microscopy 
LLC, Thornwood, NY) and imaged with a 
cooled-CCD camera system (MicroMax Princeton 
Instruments, Trenton, NJ). Images were analyzed with 
Metamorph (Universal Imaging Corporation, Down-
ingtown, PA), ImageJ (NIH), and OriginLab software 
(OriginLab Corporation, Northampton, MA). 
CD44 immunocytochemistry 
The expression of CD44 in both the YES-2CSC 
and YES-2 lines was examined as described previ-
ously 28. Briefly, each cell line was cultured on glass 
coverslips, incubated for 48 hrs, and then washed 
with PBS. Next, the cells were fixed with methanol for 
5 min, washed with PBS three times, exposed to 0.3% 
hydrogen peroxide for 3 min, and rinsed three times 
with PBS. The cells were then incubated with normal 
goat serum (NGS, Rockland, Gilbertsville, PA) at 
1:100 dilution for 30 min at room temperature fol-
lowed by mouse monoclonal anti-human CD44 anti-
body (BD Biosciences, Franklin Lakes, NJ) at 1:10 di-
lution for 2 hrs at room temperature. After three 
rinses with PBS, the cells were incubated with goat 
anti-mouse horseradish peroxidase-conjugated anti-
body (Sigma-Aldrich, St Louis, MO) at 1:40 dilution 
for 30 min and then exposed to ImmunPACT dia-
minobenzidine for 10 min (Vector Laboratories, 
Burlingame, CA). The cover slips were dehydrated in 
an ethanol series, cleared with Citrosolve (Fisher, 
Pittsburgh, PA), and mounted on glass slides with 
Permount (Fisher, Pittsburgh, PA). Control cells were 
treated identically but did not receive primary anti-
body. 
Image analysis 
The images of cell cultures immunostained for 
CD44 were analyzed with ImageJ (NIH) and 
OriginLab (OriginLab) software. Cell staining inten-
sity was determined by imaging with a 12-bit digital 
camera (MicroMax, Princeton Instruments) and a 
Zeiss Axiophot microscope. The images were 
thresholded identically using a pixel intensity 
(brightness) value of 500 analog-to-digital units 
(ADUs). For counting cells, ImageJ was used to iden-
tify cells within a normal size range (500-4000 pixels 
in area) that did not touch the edge of the image.  
Tumorsphere formation  
To examine the tumorsphere formation, CSCs 
isolated from the YES-2 line using FACS were grown 
in tissue culture plates with Complete medium as a 
monolayer until they reached near confluency. The 
cells were trypsinized, collected, and washed three 
times to remove the FBS. The cells were then cultured 
in two different ways: (1) with Complete medium in a 
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60-mm untreated petri dish or (2) with CSC medium 
consisting of DMEM-F12 supplemented with 20 
ng/ml EGF, 20 ng/ml bFGF and B27 supplement 
(Invitrogen, Carlsbad, CA, USA) in a 60-mm ultra-low 
attachment plate (Corning Life Sciences, Tewksbury, 
MA). Cells were plated at a density of 104 cells/ plate 
and incubated in a humidified atmosphere with 5% 
CO2 at 37°C. One week later, plates were examined for 
tumorsphere formation using an inverted microscope. 
The tumorspheres were collected by gentle centrifu-
gation, counted, and dissociated into single cells by 
treatment with trypsin-EDTA and mechanical dis-
ruption using a glass Pasteur pipette. The resulting 
single cells were resuspended in CSC medium or 
Complete medium, washed with PBS, and plated to 
allow tumorspheres to form again. Tumorspheres 
were passaged every 5-7 days when they reached a 
diameter about 100 μm. 
Tumorsphere staining with Aldefluor 
To assess the ability of ACAM to identify 
ALDH1 activity in tumorspheres, Aldefluor was ap-
plied to tumorspheres cultured in CSC medium and 
tumorspheres cultured in Complete medium in petri 
dishes. Cover slips were rinsed with HBSS, and then 1 
ml of Aldefluor Buffer was added to 15 μl of activated 
Aldefluor and 100 μl of this solution was applied to 
the coverslips for 45 min in a 37°C incubator. Next, the 
Aldefluor reagent was removed, tumorspheres were 
rinsed with HBSS, and propidium iodide (330 µg/ml) 
was applied for 5 min. The cover slips were washed 
three times with HBSS and the tumorspheres were 
imaged with a digital camera (MicroMax, Princeton 
Instruments) and a Zeiss Axiophot microscope. 
Another group of tumorspheres were collected, 
cultured on cover slips as attached tumorspheres in 
Complete or CSC medium and incubated at 37°C in a 
humidified incubator containing 5% CO2. In this case, 
the tumorspheres were allowed to attach in a thin film 
of medium for only 12 hrs before they were treated 
with Aldefluor for 45 min at 37°C and then propidium 
iodide as above just before imaging. Another group of 
tumorspheres was not allowed to attach but was in-
stead treated with Aldefluor, washed with HBSS by 
centrifugation, treated with propidium iodide, and 
then washed with HBSS. This low-speed 250 x g cen-
trifugation caused the tumorspheres to fragment into 
cell clusters. 
Effect of curcumin on tumorspheres 
To determine the effect of curcumin on the 
growth of YES-2CSCs tumorspheres, spheres were 
counted and cultured with 40 or 60 µM curcumin and 
0.2% DMSO in Complete medium for 30 hrs. After 
incubation, tumorspheres were counted, the medium 
was replaced with Complete medium without cur-
cumin and incubated at 37°C for four days to allow 
tumorspheres that survived the treatment to grow. 
Tumorspheres were imaged after 30 hrs or 4 days of 
treatment. Control tumorspheres were given medium 
containing 0.2% DMSO. 
To determine the effect of curcumin on tu-
morsphere formation, tumorspheres were collected, 
dissociated into single cells using trypsin-EDTA and 
mechanical disruption with a glass Pasteur pipette. 
Resulting dissociated cells were resuspended in 
Complete medium and washed by centrifugation. To 
allow tumorspheres to form, cells were plated at a 
density of 105 cells per 60-mm petri dish and either 
treated with 40 µM curcumin after four days of plat-
ing or treated with 60 µM curcumin at the time of 
plating and then incubated for 30 hrs, rinsed, and 
imaged.  
Tumorsphere proliferation 
To compare the growth of cells derived from 
dissociated tumorspheres that were made from 
YES-2CSC with the ones made from the original 
YES-2CSC cell line, tumorspheres were enzymatically 
dissociated as described above, and 103 cells/well 
were cultured in 12-well plates (Corning Life Scienc-
es). The YES-2CSC line was plated at the same densi-
ty. The cells were incubated for 10 days at 37°C in 5% 
CO2. Cell proliferation was assayed with the crystal 
violet staining method as described previously 28. 
Statistical analysis 
Statistical analyses were performed using 
OriginPro 7.5 (OriginLab). Statistical comparisons 
between two groups were made using Student’s t-test. 
For comparing more than two groups, one-way anal-
ysis of variance (ANOVA) was used followed by the 
Scheffe multiple comparisons test with a significance 
of p<0.05. Variance was indicted as standard error of 
the mean (SE). 
Results 
Isolation of cancer stem cells using Aldefluor 
and FACS 
The Aldefluor assay was used to assess the 
presence of the subpopulation with high-ALDH en-
zyme activity within the YES-2 cell line. Cell suspen-
sions were exposed to Aldefluor and then sorted by 
FACS to count and collect the CSCs. Cell sorting re-
sults without Aldefluor treatment (control) is shown 
in Figure 1A. A subpopulation with distinct fluores-
cence was present after Aldefluor treatment (Figure 
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1B). When the ALDH inhibitor DEAB was applied at 
the concentration suggested by the manufacturer (and 
also used by others 46-48) fluorescence was reduced 
(shifted to the left) and a gate was drawn to delineate 
the upper limit of these cells (Figure 1C). This gate, 
also shown in Figure 1B, was used to select for the 
ALDH high-staining subpopulation in the following 
cell sorting which used Aldefluor alone. The per-
centage of these highly fluorescent cells was 1.2% of 
the YES-2 cell line and these cells were considered the 
most stem-like cell subpopulation (YES-2CSC). 
 
 
 
 
Fig 1. Flow cytometric isolation of cancer stem cells based on 
ALDH activity. A: untreated control cells. B: Aldefluor-treated YES-2 
cells in the absence of ALDH enzyme inhibitor DEAB. C: Aldefluor-treated 
YES-2 cells in the presence of DEAB. The red line shows the gate used to 
select for cells with high ALDH activity. SSC: side scatter. 
 
Detection of Aldefluor fluorescence in at-
tached ESCC cell lines 
To identify CSCs in monolayer cultures, we ap-
plied Aldefluor to the attached ESCC cell lines. Fluo-
rescence staining was detected in the cytoplasm of all 
eight lines, including the YES-2CSC and YES-2S cell 
lines as shown in Figure 2A. Measuring the staining 
intensity of ALDH activity of individual cells indi-
cated significant differences among the mean intensi-
ties of the cell lines (ANOVA, F=151.968, p<0.0001) 
(Figure 2B). The order from high to low mean staining 
intensity was as follows: KY-5, KY-10, YES-2CSC, 
YES-1, TE-8, YES-2, TE-1, YES-2S (Figure 2C). KY-5 
cells had significantly higher mean Aldeflour staining 
than all the other cell lines (0<0.05, Scheffe test). The 
range was 122 ±2.82 (YES-2S) to 320 ±6.01 (KY-5) an-
alog-to-digital units (ADUs). There was no significant 
difference between KY-10, YES-2CSC, YES-1, and 
TE-8, whereas all of the other lines were distinctly 
different from each other and from this intermediate 
group. When YES-2 and the two YES-2-derived lines 
were compared, they were found to be significantly 
different (ANOVA, F=136.5, p<0.0001). YES-2CSC 
had significantly higher ALDH activity than the 
original YES-2 line (Figure 2D), which was in turn 
higher than the curcumin-surviving line YES-2S 
(p<0.05). 
CD44 expression in YES-2 cell lines 
As a second measure of stemness, im-
munostaining for the CSC marker CD44 was used. 
YES-2CSC and the original line exhibited distinct high 
and low-staining cells. The mean intensity between 
the sorted (YES-2CSC) and original (YES-2) cell lines 
was significantly different based on t-test (two-tailed, 
t=-2.919, p=0.0036). YES-2CSC showed a higher per-
centage of positive cells (Figure 3).  
Formation of tumorspheres  
Tumorspheres were formed from YES-2CSC in 
two different ways: Cells were either grown in a 
standard CSC medium in low-attachment plates 
(Figure 4B) or in Complete medium in Petri plates 
(Figure 4A). In both cases, tumorspheres formed 
readily within one week. The tumorspheres formed in 
Complete medium were more numerous, but the 
CSC-medium tumorspheres were significantly more 
circular according to ImageJ (0.923 ±0.0049 vs. 0.887 
±0.0053, t-test, t=-4.949, p<0.0001). The average num-
ber of tumorspheres identified in Complete medium 
was higher (74 ±3.21) than in the CSC-medium (28.3 
±1.20), n=3 plates each. When tumorspheres made 
from YES-2CSC were dissociated and plated in Com-
plete medium, the resulting monolayer cultures pro-
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liferated about twice as fast as monolayer cultures 
derived from the original YES-2CSC line during 10 
days of culture (0.0880 ±0.00221 vs. 0.0401 ±0.00477, t= 
-9.11, p<0.0001). 
 
 
Fig 2. Fluorescence intensity of ALDH1 reaction product in ESCC lines. A: Fluorescence in the ESCC lines, including YES-2CSC and YES-2S, 
after Aldefluor was applied to attached cells growing in culture. Scale bar = 100 µm B: Histograms showing the distribution of relative ALDH activity in the 
ESCC lines. C: Mean intensity of all ESCC lines. YES-2CSC is enriched in CSCs, and YES-2S is CSC-depleted. Oval indicates lines that are not significantly 
different from each other. Asterisks indicate the significantly different YES-2 lines. D: YES-2CSC compared with YES-2 to indicate the increase in stem-like 
cells in YES-2CSC. ADUs = Analog-to-digital units 
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Fig 3. CD44 immunocytochemistry. Above: CD44-stained cells are visible in YES-2 and in the YES-2CSC line which has high-Aldefluor staining as 
selected by FACS. Below: High CD44-staining cells are more abundant in the YES-2CSC line than in the YES-2 line. Scale bar = 100 µm 
 
 
Fig 4. Tumorspheres derived from YES-2CSC. YES-2CSC cells form tumorspheres when cultured in Complete medium in a Petri dish (A) or in CSC 
medium in a low-attachment plate (B). Scale bar = 100 µm  
 
Live tumorspheres labeled with Aldefluor 
To test whether ACAM would effectively iden-
tify the stem-like cells within tumorspheres, Aldefluor 
was applied to tumorspheres made from YES-2CSC in 
Complete medium and in CSC medium. The entire 
sphere showed the fluorescent product of Aldefluor 
in both media (Figure 5A and 5B) and in all tu-
morspheres examined. When tumorspheres were al-
lowed to partially differentiate on a glass surface, the 
cells proliferating from the tumorspheres were not 
stained with Aldefluor (Figure 5C and 5D). These 
results indicate that Aldefluor selects for the more 
stem-like cells within the remaining tumorsphere that 
have not differentiated. To better image individual 
cells from the tumorspheres, centrifugation was used 
to gently disrupt tumorspheres, the resulting cells 
were imaged immediately and found to only be dis-
tinguishable by their distinct high or low-fluorescence 
(Figure 5E and 5F).  
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Fig 5. ALDH activity of live tumorspheres. Tumorspheres were grown in Complete medium (A) or CSC medium (B), as in Figure 4, and then tested 
for ALDH activity by applying Aldefluor for 45 min (A2, B2). Propidium iodide fluorescence indicated dying cells (A3, B3). Merged fluorescence is shown 
in A4, B4 and as an overlay in A5, B5. Tumorspheres were allowed to attach to glass coverslips for 12 hrs in Complete medium (C1-5) and CSC medium 
(D1-5). Differentiated cells present at the edges of both types of tumorspheres were not stained after applying Aldefluor (arrows). Sphere fragments 
contained both high and low-Aldefluor staining in Complete medium (E1-5) and CSC medium (F1-5). Scale bar = 100 µm 
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Fig 6. Effects of curcumin on primary and secondary tumorspheres. Left: Primary tumorspheres immediately after 40 µM (A) or 60 µM (B) 
30-hr curcumin treatment and 4 days after 60 µM 30-hr treatment (C). Control YES-2CSC tumorspheres immediately after treatment with vehicle alone 
for 30 hrs (D, E) and 4 days later (F). Note the irregular appearance of the treated tumorspheres. Right: Secondary tumorspheres, made from dissociated 
primary tumorspheres, treated with 40 µM curcumin for 30 hrs 4 days after cell plating (G). Other tumorspheres treated with 60 µM curcumin for 30 hrs 
at the time of plating and imaged immediately (H) or 4 days later (I). Control secondary tumorspheres imaged after 30 hrs of DMSO that was given after 
4 days of growth (J) or when the cells were plated (K). Unlike the treated cells, control secondary sphere cells given 30 hrs of DMSO at the time of plating 
and then imaged 4 days later formed tumorspheres (L). Scale bar = 100 µm. 
 
Sphere inhibition by curcumin treatments 
To determine the effect of curcumin on tu-
morspheres enriched with stem cells, YES-2CSC tu-
morspheres that developed in culture for 10 days 
were treated with 40 or 60 µM curcumin for 30 hrs. 
Sphere cultures were examined immediately after 
treatments and 4 days later. These primary tu-
morspheres are shown in Figure 6, left panel. Tu-
morspheres had more irregular margins when imaged 
after 30 hrs of 40 µM (Figure 6A) or 60 µM (Figure 6B) 
curcumin or, instead, 4 days after 30 hrs of 60 µM 
curcumin (Figure 6C). Control tumorspheres were 
imaged immediately (Figure 6D and 6E) and 4 days 
after treatment with 30 hrs of 0.2% DMSO (vehicle) in 
medium (Figure 6F). Also, 40 µM curcumin for 30 hrs 
significantly reduced the number of tumorspheres 
from (393 ±14.26) before to (162 ±20.69) after treatment 
(p= 0.001, t=9.192, n=3 plates). 
We also examined secondary tumorspheres that 
were formed from trypsin-dissociated tumorspheres 
(Figure 6, right panel). After 4 days of culture, these 
tumorspheres were treated with 40 µM curcumin for 
30 hrs causing them to become so irregularly-shaped 
(Figure 6G) relative to the control (Figure 6J) that they 
could not be counted reliably as spheres. Cells from 
dissociated tumorspheres were treated with 60 µM 
curcumin for 30 hrs at the time the cells were plated. 
This treatment prevented tumorspheres from forming 
when imaged immediately after (Figure 6H) and 4 
days later (Figure 6I) relative to controls (Figure 6K 
and 6L), respectively.  
Discussion 
Among the few current methods available to 
distinguish the stem-like cells from the remaining 
cancer cells is ALDH immunocytochemistry 28 or the 
standard Aldefluor enzyme assay. During the Alde-
fluor assay, a fluorescent product is deposited in live 
cells in response to the high ALDH content of CSCs. 
We expected the fluorescence intensity to vary be-
cause ALDH activity varies between CSCs due to 
differences in their differentiation state. The distribu-
tion of high Aldefluor-staining cells we detected by 
FACS in the YES-2 line is best explained by a variation 
in stem-like properties, as found in other cancer 
lines 49.  
When the ALDH1 inhibitor DEAB was used in 
the assay, cell fluorescence decreased substantially 
but remained above the unstained cell population that 
consists of non-CSCs. It appears that stemness varies 
continuously in this cell line, and possibly others, as 
indicated by the range of Aldefluor staining in the 
ACAM histograms (Figure 2). By selecting for only 
the cells at the upper range of Aldefluor fluorescence, 
where no cells remained in the DEAB-treated assay, 
we generated an additional cell line (YES-2CSC) that 
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contains, conservatively, the most stem-like compo-
nent of the YES-2 line. We suspect that many of the 
cells that stain less effectively can be considered the 
progenitor cells that are generated from CSCs and 
then proliferate and further differentiate to form the 
bulk of tumors 50, 51. Similar low-staining populations 
were present in other studies using DEAB with Alde-
fluor 46-48, 52, further supporting the idea that these are 
progenitor cells with lower ALDH activity relative to 
CSCs. To confirm this possibility of using Aldefluor to 
identify progenitor cells, additional studies should 
examine co-localization of Aldefluor with a second 
stem cell marker, such as CD44, to test for a decline in 
both markers within these putative progenitor cells in 
relation to the expression levels in CSCs.  
This heterogeneity of cells stained within the 
Aldefluor assay suggested initially that cells of a dis-
tinctly different morphology may be present in cancer 
cell lines and that the fluorescence intensity may cor-
relate with cell shape. To address this possibility, the 
Aldefluor substrate was applied to six ESCC cell lines 
using ACAM. We observed both high and 
low-staining cells, but no cells of a distinctly different 
shape or size were distinguishable by ACAM in this 
cancer cell type. 
When the cell lines were arranged according to 
mean fluorescent intensity, the order was similar to 
that of a previous study in which ALDH1A1 im-
munocytochemistry was used to characterize these 
cell lines 28, verifying the accuracy of ACAM at dis-
tinguishing between cell lines according to their CSC 
content. Specifically, the highest and lowest staining 
cell lines were the same in both assays, although not 
all intermediate-staining lines followed the same or-
der. It should be noted that ACAM is particularly 
useful with epithelial cells such as the ESCC lines be-
cause they readily form a monolayer in culture. 
Because this is the first reported use of Aldefluor 
in an attached-cell assay of stemness, we examined 
how it might be an alternative and complementary 
method to standard Aldefluor flow cytometry. First, 
we considered the limitations of the standard method. 
In addition to a lack of validation for some types of 
cancer stem cells, there are several other drawbacks 
and limitations to the Aldefluor procedure concerning 
the handling of the cells during the assay. During the 
standard Aldefluor procedure, suspended cells are 
subjected to increased cell stress in response to phys-
iological or environmental effects that monolayers do 
not experience. The suspended cells are incubated 
with the reagent for 30 to 60 min and are then kept on 
ice until cell sorting, a step that will affect overall en-
zyme activity. The cell aggregation produced during 
centrifugation and processing could cause poor access 
to oxygen or glucose and buildup of lactic acid and 
CO2 near the cells. Excessive CO2 levels produce res-
piratory acidosis that alters cell metabolism 27. In fact, 
these stressors could act differentially on CSCs and 
non-CSCs resulting in an altered ratio of these two 
subpopulations. Another known effect of the standard 
Aldefluor assay is the intentional inhibition of the 
multidrug-resistance transporter system 16. When the 
reagent is added, the efflux is specifically inhibited in 
the suspended cells by the Aldefluor Buffer and this 
suppression of the transporter can alter cell physiol-
ogy during sorting, whereas ACAM does not require 
the inhibitor during imaging thus avoiding its poten-
tial side effects. Taken together, these reasons provide 
adequate incentive to further develop ACAM as an 
alternative and complementary method to the stand-
ard flow cytometry method with Aldefluor. 
To further verify the accuracy of using Aldefluor 
on attached cells, the Aldefluor substrate was also 
applied to the original line, the curcumin-surviving 
line, and the CSC-sorted cell line (YES-2, YES-2S, and 
YES-2CSC, respectively). The results showed that 
YES-2CSC had higher Aldefluor staining than the 
other cell lines and the curcumin-surviving cells had 
the lowest. These results indicate that ACAM is ad-
vantageous for detecting CSCs in adherent cells.  
CD44 is a commonly expressed CSC marker that 
is observed in many cancer cell lines, including ESCC, 
and is also identifiable by immunostaining or FACS 28, 
53, 54. The positive CD44 cells detected in the YES-2 and 
YES-2CSC lines confirm our results from ACAM and 
Aldefluor-based FACS. The YES-2CSCs showed more 
CD44 staining than the original YES-2 line and had 
higher mean fluorescence using ACAM, indicating 
again that ACAM is able to quantify the stem-like 
state of a cancer cell line that has been enriched in 
CSCs using FACS. 
We also tested ACAM as a method to identify 
CSCs in tumorspheres using Aldefluor. A few studies 
have used Aldefluor to detect CSCs in cell suspension 
made from tumorspheres 39, 40, but no prior studies 
have used Aldefluor to stain the intact sphere. The 
results of the current report show the feasibility of this 
approach. When tumorspheres were grown by two 
different methods and then allowed to partially dif-
ferentiate, Aldefluor treatment stained a major por-
tion of all of the tumorspheres, but differentiating 
cells at the margin of the tumorspheres did not stain 
(Figure 5). To determine whether the differential 
staining we observed in monolayers of ESCC cells 
would be present in cells growing as tumorspheres, 
we applied Aldefluor to fragments produced by gen-
tle centrifugation of tumorspheres, and again both 
high and low-staining cells were present. These initial 
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results suggest that Aldefluor staining may also dis-
tinguish between CSCs, progenitor cells, and more 
differentiated cells within tumorspheres based on 
staining intensity (Figure 5). 
The stemness and number of CSCs that remains 
in a cell line previously enriched in CSCs could 
change spontaneously during repeated passaging. 
The number of YES2-CSC passages used in the tu-
morsphere experiments ranged from 2 to 9 (average 
5.8), whereas the ACAM and CD44 experiments used 
YES2-CSC cells after only 2 to 4 passages. Neverthe-
less, the ability to form primary and secondary 
spheres (Figure 6), which is an indicator of stemness, 
was not lost during passaging. Therefore, any ability 
of one cell subpopulation within YES2-CSC to grow 
faster and alter the CSC content of the cell line was not 
obvious from these results. 
Tumorspheres enriched in CSCs can be formed 
when cancer cells are cultured in serum-free medium 
supplemented with growth factors, specifically bFGF 
and EGF, during culture in low-attachment plates 55. 
Although use of this culture technique with CSC me-
dium is effective, it is costly and therefore less acces-
sible than other cell culture methods. Our study dis-
covered that use of standard CSC media with 
low-attachment plates is not required for sphere for-
mation from the YES-2CSC cell line. As a more af-
fordable alternative, we showed that ul-
tralow-attachment plates could be replaced with a 
standard non-cell culture Petri dish when the CSC 
medium is replaced with Complete medium which 
contains FBS. In contrast, when CSC medium was 
used with the Petri dish the cells attached and differ-
entiated and no tumorspheres formed (data not 
shown). The new method yielded more tumorspheres 
than the standard method, and when dissociated the 
cells proliferated faster than the original YES-2CSC 
line, suggesting that these tumorspheres had high 
CSCs content.  
Although tumorspheres formed by the two 
methods appear to be very similar, the new method 
could have produced tumorspheres with fewer CSCs. 
To further test tumorspheres made by the new 
method, we prepared tumorspheres from the 
YES-2CSC line in Complete medium and treated them 
with curcumin which is reported to more effectively 
eliminate CSCs than non-stem cells in different cancer 
cell types 56, 57. For example, our previous research 
showed a reduction in ALDH1A1-positive cells in six 
curcumin-surviving ESCC lines by immunocyto-
chemistry 28. Curcumin causes cell death in a variety 
of ways by targeting, membrane receptors, cytokines, 
kinases, and transcription factors 34. Moreover, cur-
cumin effects seem to persist despite the typical 
chemo-resistant capabilities of CSCs and even select 
against CSCs, significantly reducing the number of 
cells showing CSC-markers in colon, glioma, and 
ESCC lines 28, 56, 57.  
Our result showed that curcumin at 60 µM pre-
vented secondary sphere formation from tu-
morspheres formed by the new method and 40 µM 
produced irregularly shaped spheres. These poorly 
shaped spheres suggest that cell interactions or ex-
tracellular matrix through which CSCs communicate 
may be disrupted. A recent study by Subramaniam, et 
al., 58 showed that curcumin treatment significantly 
reduces both primary and secondary sphere for-
mation in a dose dependent manner in two ESCCs 
(TE-7 and TE-10). Similarly, we found that initial 
formation of secondary tumorspheres made by the 
new method was as effectively eliminated by 60 µM 
curcumin as tumorspheres made by the standard 
method that were given 50 µM curcumin, as reported 
previously 58. Based on these inhibitory effects of 
curcumin the new method likely produces tu-
morspheres enriched in CSCs. Furthermore, tu-
morspheres formed by both the new and standard 
methods were indistinguishable when stained by Al-
defluor. Using another approach, Aldefluor has been 
shown to stain live neural stem and progenitor cells in 
the subventricular zone of mouse brain following 
intraventricular injection of the reagent 59, supporting 
novel use of Aldefluor, including ACAM, for identi-
fying CSCs by microscopy. 
Conclusion 
Our study demonstrated the feasibility of iden-
tifying CSCs by using Aldefluor to stain live attached 
cells growing as monolayers. The benefit of detecting 
CSCs in attached cells with Aldefluor, rather than in 
cell suspensions, is that the cells can be imaged di-
rectly to evaluate morphology and intracellular dy-
namics of live cells. We also introduced and evaluated 
an alternative method for forming tumorspheres us-
ing ordinary Petri dishes and Complete medium. The 
finding that both YES-2CSC monolayers and tu-
morspheres are sensitive to curcumin provides fur-
ther evidence that one of the mechanisms by which 
curcumin inhibits cancer cell growth is by targeting 
CSCs. It is likely that the two new methods intro-
duced in this paper for detecting CSCs and producing 
tumorspheres would be valuable when used in CSC 
studies of other cancers. 
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